help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2005-0197
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/2/268    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yin, Y.
Right arrow Articles by Glazer, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yin, Y.
Right arrow Articles by Glazer, R. I.
Molecular Endocrinology 20 (2): 268-278
Copyright © 2006 by The Endocrine Society

3-Phosphoinositide-Dependent Protein Kinase-1 Activates the Peroxisome Proliferator-Activated Receptor-{gamma} and Promotes Adipocyte Differentiation

Yuzhi Yin, Hongyan Yuan, Chenguang Wang, Nagarajan Pattabiraman, Mahadev Rao, Richard G. Pestell and Robert I. Glazer

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C. 20007

Address all correspondence and requests for reprints to: Robert I. Glazer, Georgetown University School of Medicine, Research Building, Room W318, 3970 Reservoir Road, Northwest, Washington, D.C. 20007. E-mail: glazerr{at}georgetown.edu.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Adipocyte differentiation is regulated largely through the actions of the peroxisome proliferator-activated receptor (PPAR) {gamma} nuclear receptor and the insulin signaling pathway. 3-Phosphoinositide-dependent protein kinase-1 (PDK1) serves as a critical regulatory point in insulin signaling through its ability to phosphorylate the activation loop of several protein kinase families. The present study was undertaken to determine the interrelationships between the PDK1 and PPAR{gamma} signaling pathways, and their association with adipocyte differentiation. Coexpression of PDK1 and PPAR{gamma}1 in 293T cells stimulated PPAR{gamma} response element-dependent reporter gene activity in either the presence or absence of ligand. PDK1-mediated stimulation of PPAR{gamma}1 activity was comparable in magnitude to the coactivator activated in breast cancer-1, and was blocked by either the corepressor silencing mediator of retinoid and thyroid hormone receptor or dominant-negative PAX8-PPAR{gamma}1. Heterologous Gal4-PPAR{gamma}1 assays indicated that PDK1 interacted with the ligand binding domain, and physically associated with PPAR{gamma}1; however, PDK1-mediated stimulation was not dependent on phosphorylation of PPAR{gamma}1 by PDK1. PDK1 stimulatory activity was eliminated by mutation of the {alpha}-helical hydrophobic motifs in PDK1, L268XII, and V313XXLL, and expression of the {alpha}-helical region encompassing these motifs stimulated PPAR{gamma} response element-dependent transcription. PDK1-PPAR{gamma} interaction was confirmed by chromatin immunoprecipitation analysis of the lipoprotein lipase and adipocyte fatty acid-binding protein promoters. In cells expressing PDK1 and PPAR{gamma}, binding to PPAR{gamma} response elements occurred, which was enhanced by treatment with a PPAR{gamma} agonist. Expression of PDK1 in 3T3-L1 or COMMA-1D mammary epithelial cells promoted adipocyte differentiation in the presence of a PPAR{gamma} agonist that was comparable to the response of PPAR{gamma}1-transfected cells in the presence of agonist; expression of PDK1 and PPAR{gamma} resulted in a synergistic effect. Adipocyte differentiation in the presence of a PPAR{gamma} agonist was markedly attenuated in PDK1 null cells. These results suggest that PDK1 can function as a PPAR{gamma}1 coactivator independently of its catalytic activity and establishes an important mechanistic link between adipocyte differentiation and the insulin signaling pathway.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
PDK1 (3-PHOSPHOINOSITIDE-dependent protein kinase-1) was first characterized as a protein kinase B (AKT) kinase in extracts of skeletal muscle and brain (1, 2) and serves as a central mediator of growth factor receptor-coupled activation of phosphatidylinositol 3-kinase (PI3-K) (3) through transphosphorylation of a common motif in the activation loop of AKT and other protein kinase families (4, 5). The PI3-K pathway plays a critical role in insulin signaling, where its impairment can lead to type II diabetes (6). Insulin-dependent processes, such as adipocyte differentiation, are equally dependent on activation of the PI3-K/AKT axis, as shown by the ability of constitutively active AKT to promote spontaneous adipocyte differentiation in 3T3-L1 cells (7). Indeed, an inactivating mutation in AKT2 is associated with a familial form of insulin resistance and diabetes (8).

Peroxisome proliferator-activated receptor (PPAR) {gamma} is a member of the ligand-dependent nuclear hormone receptor family (9) and serves as a receptor for the thiazolidinedione class of antidiabetic agents that enhance insulin sensitization in peripheral tissues (10). PPAR{gamma} is particularly abundant in adipose tissue (11) and stimulates adipogenesis in fibroblasts (12) through activation of adipocyte gene expression (13, 14, 15). Overexpression of constitutively active PPAR{gamma} in 3T3-L1 preadipocytes induces adipocyte differentiation, and this effect is blocked by dominant-negative PPAR{gamma} (16). Although PPAR{gamma}-mediated transactivation is enhanced by insulin (17), the mechanistic link between nuclear receptor activation, insulin signaling, and adipocyte differentiation has not been established. In the present study, evidence is presented for the coassociation of PDK1 and PPAR{gamma}1, the ability of PDK1 to act as a PPAR{gamma} coactivator, and the ability of PDK1 to induce adipocyte differentiation in the presence of a PPAR{gamma} agonist.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
PDK1 Enhances PPAR{gamma} Transactivation
PPAR{gamma}-dependent transcription was assessed with a PPAR{gamma} response element (PPRE)-dependent reporter gene in the absence and presence of the highly selective PPAR{gamma} ligand GW7845 (Fig. 1AGo). Expression of PDK1 alone did not affect endogenous PPAR{gamma} activity, but coexpression of PDK1 and PPAR{gamma}1 resulted in a 2- to 3-fold stimulation of reporter activity compared with PPAR{gamma}1 alone in the presence or absence of ligand. Dominant-negative Pax8-PPAR{gamma}1 suppressed transactivation in all instances (Fig. 1AGo). The stimulatory activity of PDK1 on PPAR{gamma} was comparable to the activity of the coactivator activated in breast cancer-1 (AIB1) (18, 19), but PDK1 and AIB1 did not produce an additive effect, suggesting that they interacted at a common site within PPAR{gamma} (Fig. 1BGo). The corepressor silencing mediator of retinoid and thyroid hormone receptor (SMRT) completely blocked ligand-independent activation of PPAR{gamma} and partially inhibited ligand-dependent stimulation in the presence or absence of PDK1 (Fig. 1BGo). Immunoprecipitation (IP)/Western blot assays were next carried out to determine whether activation of PPAR{gamma} by PDK1 was due to direct protein-protein interaction (Fig. 1CGo). PDK1 coimmunoprecipitated with PPAR{gamma}, and vice versa, suggesting specific physical interaction.


Figure 1
View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1. PDK1 Activates PPAR{gamma} Transcriptional Activity

A, Cells were transfected with a p3XPPRE-TK-Luciferase plasmid and either empty vector (Vector), PDK1 (PDK1), PPAR{gamma} (PPAR), or PAX8-PPAR{gamma} (PAX8-PPAR) alone and in combination. Cells were treated 24 h after transfection with 1 µM GW7845, and luciferase activity determined 24 h later. Activity is expressed as the fold change in activity compared with cells transfected with empty vector in the absence or presence of GW7845. Each value is the mean ± SEM of three to six determinations. B, Cells were transfected as in panel A except that AIB1 (AIB1) and SMRT (SMRT) were evaluated alone and in combination with PDK1 and PPAR{gamma}. Each value is the mean ± SEM of three to six determinations. C, Cells were cotransfected with PPAR{gamma} (PPAR) and PDK1 (PDK1), and cell lysates immunoprecipitated with either IgG (IgG), anti-PDK1 (PDK1) or anti-PPAR{gamma} (PPAR{gamma}). Immunoprecipitates were separated by SDS-PAGE in 10% Tris-glycine gels, transferred onto nitrocellulose and Western blotting (WB) carried out with either PPAR{gamma} or PDK1 antibodies. DMSO, Dimethylsulfoxide.

 
PDK1 Binds to the Ligand Binding Domain (LBD)
To map the PPAR{gamma} domain interacting with PDK1, heterologous reporter assays with Gal4-PPAR{gamma} fusion proteins were carried out (Fig. 2AGo). PDK1 stimulated Gal4-PPAR{gamma} activity to a comparable degree as the wild-type receptor (Fig. 1Go), and a more pronounced effect was noted with Gal4-PPAR{gamma} LBD (Fig. 2AGo). Both Gal4-PPAR{gamma} and Gal4-PPAR{gamma}/LBD coimmunoprecipitated with PDK1 (Fig. 2BGo) corroborating the results with the native protein (Fig. 1CGo). These data indicate that coactivation with the Gal4 fusion proteins by PDK1 is a direct interaction with the receptor LBD.


Figure 2
View larger version (9K):
[in this window]
[in a new window]
  		Fig. 2. PDK1 Interacts with the PPAR{gamma} LBD

A, Cells were transfected with pG5Luciferase and either empty vector (vector), PDK1 (PDK1), Gal4-PPAR{gamma} (Gal4-PPAR), Gal4-PPAR{gamma}/LBD (Gal4-PPAR/LBD) alone or in combination. Luciferase activity was determined as described in Fig. 1AGo. Activity is expressed as the fold change in activity compared with cells transfected with empty vector in the absence or presence of GW7845. Each value is the mean ± SEM of three determinations. B, PDK1 binds to the PPAR{gamma} LBD. Cells were transfected with PDK1 (PDK1) and either an empty Gal4 vector (Gal4 vector), Gal4-PPAR{gamma} (PPAR{gamma}) or Gal4-PPAR{gamma}/LBD (PPAR{gamma}/LBD). Cell lysates were immunoprecipitated with an anti-Gal4 (Gal4) antibody, and the immunoprecipitate separated by SDS-PAGE, transferred onto nitrocellulose, and probed with an anti-PDK1 antibody. WB, Western blot.

 
PDK1 Does Not Phosphorylate PPAR{gamma}
To determine whether the stimulatory effect of PDK1 on PPAR{gamma} transactivation was due to phosphorylation, a putative PDK1 phosphorylation motif in PPAR{gamma}, S225FxxT resembling T308FxxT in the AKT activation loop, was mutated (Fig. 3AGo). The S225A mutation did not affect coactivation of PPAR{gamma} by PDK1. Furthermore, kinase-dead PDK1 (KD-PDK1) did not transactivate PPAR{gamma} (Fig. 3AGo). To directly determine whether PPAR{gamma} served as a PDK1 substrate in vitro kinase assays were also carried out with rPDK1 and a glutathione-S-transferase (GST)-PPAR{gamma} fusion protein or recombinant SGK (serum- and glucocorticoid-activated protein kinase) as substrates (Fig. 3BGo). Although PDK1 did phosphorylate SGK, it did not phosphorylate GST-PPAR{gamma}, again indicating that PPAR{gamma} coactivation by PDK1 was not phosphorylation dependent.


Figure 3
View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3. Phosphorylation Is Not Required for PDK1-Dependent Activation of PPAR{gamma}

A, Cells were transfected with a p3XPPRE-TK-Luciferase plasmid and either empty vector (Vector), PPAR{gamma} (PPAR), PPAR{gamma}/S225A (PPAR/S225A) in the presence and absence of PDK1 (PDK1) or kinase-dead PDK1 (KD-PDK1). Luciferase activity was determined as described in Fig. 1AGo. Activity is expressed as the fold change in activity compared with cells transfected with empty vector in the absence and presence of GW7845. Each value is the mean ± SEM of three determinations. B, rPDK1 was incubated in kinase buffer with [{gamma}32P]-ATP and either GST-PPAR{gamma} or rSGK as substrate for 30 min at 30 C. The reaction was stopped with SDS-sample buffer, separated by SDS-PAGE in a 10% Tris-glycine gel, transferred onto nitrocellulose and phosphorylation determined by autoradiography. Autophosphorylated PDK1 and phosphorylated SGK were present, but PPAR{gamma}1 was not phosphorylated. DMSO, Dimethylsulfoxide; WB, Western blot.

 
PDK1 Contains Coactivator Motifs
The PDK1 catalytic domain (20) contains two hydrophobic domains similar to the LXXLL motif found in PPAR{gamma} coactivators (21), 275LQYII271 and 313VXXLL317 present in {alpha}-helices F and H, respectively. Introduction of double point mutations I271R/I272R and L316R/L317W in PDK1 eliminated its ability to coactivate PPAR{gamma} (Fig. 4AGo). To determine whether the PDK1 sequence encompassing {alpha}-helices F through H could directly coactivate PPAR{gamma}, residues 256–322 in the PDK1 catalytic domain were amplified and coexpressed with PPAR{gamma}, and reporter activity was determined (Fig. 4BGo). Remarkably, PDK1 [256–322] exhibited almost full coactivator activity, providing direct evidence that this domain can mediate nuclear receptor coactivation through a unique phosphorylation-independent mechanism.


Figure 4
View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4. PDK1 Coactivation Resides in {alpha}-Helices F and H

PDK1 {alpha}-helices F and H are depicted at the top of the figure. A, Cells were transfected with p3XPPRE-TK-Luciferase and either empty vector (vector), PPAR{gamma} (PPAR), PDK1/I271R-I272R (PDK1/I271R-I272R) or PDK1/L316R-L317W (PDK1/L316R-L317W) alone and in combination. Luciferase activity was determined as described in Fig. 1AGo. Activity is expressed as the fold change in activity compared with cells transfected with empty vector in the absence or presence of GW7845. Each value is the mean ± SEM of three determinations. B, Cells were transfected with p3XPPRE-TK-Luciferase and either empty vector (Vector), PPAR{gamma} (PPAR) or PDK1 [256–322] (PDK1 [256–322]) alone and in combination. Luciferase activity was determined as described in Fig. 1AGo. Activity is expressed as the fold change in activity compared with cells transfected with empty vector in the absence and presence of GW7845. Each value is the mean ± SEM of three determinations. DMSO, Dimethylsulfoxide.

 
PDK1 and PPAR{gamma} Associate at PPAR Response Elements
To assess the coactivation potential of PDK1 on PPAR{gamma}, chromatin immunoprecipitation (ChIP) analysis of the PPRE within the lipoprotein lipase (LPL) and adipocyte fatty acid-binding protein (aP2) promoters (22, 23) was assessed in cells expressing PDK1 and PPAR{gamma} (Fig. 5Go). IP with either PDK1 or PPAR{gamma} antibodies revealed transcription complexes on the LPL and aP2 PPRE promoter regions, which were enhanced by treatment with the PPAR{gamma} agonist GW7845. These results are consistent with PPRE-dependent reporter analysis in cells expressing PDK1 and PPAR{gamma} (Fig. 1Go), and further indicate the nuclear localization of PDK1.


Figure 5
View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5. ChIP Analysis of PPRE-Containing Promoter Regions

Cell lysates from COMMA-1D mammary epithelial cells expressing either empty virus or PPAR{gamma} and PDK1 were treated with 0.1 µM GW7845 or 0.01% dimethylsulfoxide and analyzed by ChIP assay as described in Materials and Methods. Lysates were immunoprecipitated with either a PPAR{gamma} or PDK1 antibody and the PPRE-containing promoter regions of aP2 and LPL were amplified by PCR.

 
PDK1 Is Required for Adipocyte Differentiation
To assess a functional role for PDK1 in adipocyte differentiation, 3T3-L1 preadipocytes were transfected with the various constructs and primed with insulin and a suboptimal concentration of the PPAR{gamma} ligand rosiglitazone (Fig. 6Go). Cells transfected with either PDK1 or PPAR{gamma} exhibited adipocyte differentiation in the presence of rosiglitazone, and expression of both proteins produced a synergistic effect. Differentiation was low in cells transfected with either the empty vector or KD-PDK1. Adipocyte differentiation was not observed in the absence of rosiglitazone (results not shown). These results suggest that PDK1 was capable of inducing adipocyte differentiation only in cells primed with a PPAR{gamma} ligand, and that differentiation was ligand dependent, as shown previously (24). To determine whether PDK1 expression affected the level of PPAR{gamma}, 3T3-L1 cells were analyzed by Western blotting (Fig. 6CGo). PDK1 did not significantly alter PPAR{gamma} levels, suggesting that the stimulatory effect of PDK1 on differentiation was not due to altered PPAR{gamma} expression. Adipocyte differentiation was also examined in mouse mammary epithelial cells in the presence of the PPAR{gamma} ligand GW7845 (Fig. 6DGo). Cells transduced with either an empty virus or PDK1 did not undergo differentiation in the presence of GW7845; however, PPAR{gamma}-expressing cells and notably cells expressing both PDK1 and PPAR{gamma} exhibited significant differentiation that was blocked by treatment with the PI3K inhibitor LY294002.


Figure 6
View larger version (71K):
[in this window]
[in a new window]
  		Fig. 6. PPAR{gamma} and PDK1-Dependent Adipocyte Differentiation in Preadipocytes and Mammary Epithelial Cells

A, 3T3-L1 cells were transfected with either empty vector (Vector), PDK1 (PDK1), PPAR{gamma} (PPAR{gamma}), PPAR{gamma} (PPAR{gamma}), PPAR{gamma}+PDK1+ (PPAR{gamma}+PDK1), KD-PDK1 (KD-PDK1) or PPAR{gamma}+KD-PDK1+ (PPAR{gamma}+KD-PDK1). After transfection, cells were treated with 5 µg/ml insulin for 24 h, and subsequently with 0.5 µM rosiglitazone for 7 d. Cells were then washed with PBS, fixed, and stained with Oil Red O for lipids as described in Materials and Methods. Magnification, x100. B, Adipocyte differentiation in panel A was quantified by counting the number of Oil Red O stained cells in each of three microscopic fields. Each value is the mean ± SD of three fields. C, 3T3-L1 cells were transfected with PDK1 as in panel A and PPAR{gamma} levels determined by Western blot. D, Mouse mammary epithelial cells were retrovirally transduced with either empty virus (Vector), PDK1 (PDK1), KD-PDK1 (KD-PDK1), PPAR{gamma} (PPAR{gamma}), PPAR{gamma}+PDK1+ (PPAR{gamma}+PDK1) or PPAR{gamma}+KD-PDK1 (PPAR{gamma}+KD-PDK1), and grown in 12-well plates for 24 h. Differentiation was induced as described in panel A except that 1 µM GW7845 was used as the PPAR{gamma} agonist in all instances. Cells expressing PPAR{gamma} (PPAR{gamma}) and PPAR{gamma}+PDK1 (PPAR{gamma}+PDK1) were also treated with 10 µM LY294002 in the presence of GW7845. Cells were stained with Oil Red O as in panel A. Magnification, x100. E, Quantitation of adipocyte differentiation in mouse mammary epithelial cells. Cells were treated as described in panel D and lipids quantitated using AdipoRed and measuring fluorescence. Each value is the mean ± SD of three determinations.

 
The dependence of adipocyte differentiation was also assessed in PDK1 null embryonic stem cells in the presence and absence of rosiglitazone (Fig. 7Go). PPAR{gamma} ligand rosiglitazone induced intense adipogenesis in wild-type ES cells that was markedly attenuated in PDK1 (-/-) cells, suggesting that PDK1 has a dominant role in promoting adipocyte differentiation.


Figure 7
View larger version (119K):
[in this window]
[in a new window]
  		Fig. 7. Adipocyte Differentiation in PDK1 Null Cells

Rosiglitazone (Rosi)-induced adipocyte differentiation in embryonic stem cells with homozygous disruption of PDK1. Wild-type or PDK1 (–/–) ES cells were grown in 12-well plates for 24 h and treated with 10 nM trans-retinoic acid for 9 d, followed by treatment with 1 µM rosiglitazone for 10 d. Cells were stained with Oil Red O for the presence of fat droplets in adipocytes as described in Materials and Methods. Upper four panels, x100; lower panels, x40.

 
PDK1 and PPAR{gamma} Modeling
PDK1 contains two LXXLL-like domains, 275LXXII271 and V313XXLL317 in {alpha}-helices F and H, respectively, within the catalytic domain (20) (Fig. 8Go). Based on the known crystal structure of PDK1 and PPAR{gamma}, it is proposed that in order for helices F and H to interact with PPAR{gamma}, they have to be exposed in a folded conformation where either 275LXXII271 or V313XXLL317 interacts with the coactivator domain, and the other {alpha}-helix provides the necessary hydrophobic core to orient the helical domain interaction (Fig. 8Go).


Figure 8
View larger version (31K):
[in this window]
[in a new window]
  		Fig. 8. Predictive Model of PDK1 Binding to PPAR{gamma}

A, In the PDK1 catalytic domain, the F-helix is shown as a magenta ribbon, the H-helix is shown as a green ribbon and the G-helix is shown as a cyan ribbon (20 50 ). The loops between helices F, G, and H are shown as orange ribbons. The ATP molecule is shown as a ball-and-stick model. The four mutated residues are labeled. B, Using the reported crystal structure of the complex between a coactivator and PPAR{gamma} (48 50 ), an energy minimized model of the complex between PPAR{gamma} and PDK1 {alpha}-helices F, G, and H was generated. A ribbon representation of the model of a coactivator sequence (shown in magenta) interacting with the coactivator binding site of PPAR{gamma} is shown. The binding of the coactivator domain to PPAR{gamma} keeps helix-12 in the agonist conformation. PPAR{gamma} is represented by the gray colored ribbon, except for helix-12 (yellow) and the coactivator binding region (blue). C, A perpendicular view (B).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
MATERIALS AND METHODS
 REFERENCES
 
PPAR{gamma} regulates a variety of metabolic functions that modulate growth, differentiation, and apoptosis in a variety of cell types (9, 25, 26). One function in particular is its ability to regulate adipogenesis (27, 28) through its interaction with several coactivators (29, 30) and possibly by its negative regulation by ERK2 and JNK (31). PDK1 occupies a central point between receptor-mediated activation of PI3K and several downstream effectors of insulin signaling (32), such as AKT (6, 33), through phosphorylation of the activation loop. Due to the seemingly common roles of PDK1 and PPAR{gamma} in insulin signaling and adipocyte differentiation, and the ability of PDK1 to shuttle between the nucleus and cytosol (34), we investigated whether PDK1 could interact with PPAR{gamma} and modulate its transcriptional activity.

Remarkably, PDK1 activated and physically associated with PPAR{gamma} independently of phosphorylation. The inability of KD-PDK1 to act as a coactivator was likely due to the adoption of a different conformation for the G and H {alpha}-helices compared with the wild-type enzyme as shown for PDK1(S241A) (20, 35). Recently, a phosphorylation-independent mechanism was reported for the interaction between the N-terminal noncatalytic domain of PDK1 and Ral-GEF (36). In addition, the activation of PPAR{gamma} by MAPK kinase 5 independently of phosphorylation was associated with its interaction with the hinge region of PPAR{gamma} (37).

Although PDK1 can translocate to the nucleus, it is not known whether nuclear sequestration is associated with a specific transcriptional function (34). We show for the first time that PDK1 and PPAR{gamma} interact at the PPRE of two PPAR{gamma}-dependent promoter regions, indicating nuclear localization. PDK1 appeared to function as a coactivator in a manner similar to AIB1 because both proteins activated transcription in a mutually exclusive manner (Fig. 1BGo). Coactivation is believed to be dependent on ligand binding, where a conformational shift in the AF2 domain (19) allows association of the coactivator with the AF2-modified hydrophobic pocket in the LBD region to allow formation of the coactivator complex (38). Although coactivation occurred in the absence of ligand, PDK1-PPAR{gamma} interaction was markedly enhanced by GW7845 in both reporter and ChIP assays (Figs. 1Go and 5Go). This suggests that PDK1 prevented the recruitment of corepressors such as SMRT (39), an effect that was further enhanced by ligand. Indeed, SMRT completely suppressed PDK1-mediated coactivation (Fig. 1BGo).

Although PDK1 did not phosphorylate PPAR{gamma}, it did physically associate with the receptor that associated with PPRE in two PPAR{gamma}-activated genes (Fig. 5Go). All coactivators contain an LXXLL motif in an {alpha}-helical domain (38), and PDK1 contains the LXXLL-like domains 275LXXII271 and V313XXLL317 in {alpha}-helices F and H, respectively (20) (Fig. 4Go). Expression of {alpha}-helices F through H (PDK1[256–322]) acted similarly to the holoenzyme, and mutation of either LXXLL-like motifs eliminated PPAR{gamma} activation, suggesting they act in a cooperative manner. It is not clear which domain is primary because mutation of either motif eliminated activity (Fig. 4Go), suggesting a destabilization of the hydrophobic core formed by helices F, G, and H.

Activation of PPAR{gamma} in either preadipocytes or mammary epithelial cells resulted in adipogenesis. These results are consistent with previous studies showing the adipocyte-enhancing effect of PPAR{gamma}2 expression in fibroblasts (12, 40), and the dependence of adipocyte differentiation during development on PPAR{gamma} (41) through its regulation of programmed adipocyte-specific gene expression (15). Overexpression of PDK1 in preadipocytes treated with a PPAR{gamma} ligand led to enhanced differentiation (Fig. 6Go), an effect that was blocked by kinase-dead PDK1. PDK1 similarly enhanced PPAR{gamma}-mediated adipocyte differentiation in mammary epithelial cells, a process that was blocked by the PI3K inhibitor LY294002, and is consistent with a recent report indicating the ability of secretory mammary epithelial cells to undergo adipocyte differentiation (42). Interestingly, PDK1 null cells exhibited an attenuated response to rosiglitazone, indicating the importance of the PDK1 signaling pathway in adipocyte differentiation. PPAR{gamma} agonists such as rosiglitazone regulate PPAR{gamma}-mediated transcription by promoting the dissociation of corepressors and recruitment of coactivators (43). Our data further suggest that PDK1 may regulate adipogenesis by serving as a coactivator of PPAR{gamma}.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
REFERENCES
 
Cell Culture and Reagents
293T, 3T3-L1, and mouse mammary epithelial COMMA-1D cells were obtained from the Tissue Culture Shared Resource, Lombardi Comprehensive Cancer Center. 293T and 3T3-L1 cells were maintained in DMEM supplemented with 10% fetal calf serum (FCS) at 37 C under 5% CO2. COMMA-1D cells were maintained in DMEM/F12 medium (Sigma-Aldrich Chemical Co., St. Louis, MO) supplemented with 5% FCS at 37 C under 5% CO2. Mouse embryonic stem cells with homozygous deletion of PDK1 were kindly provided by Dr. Dario Alessi, University of Dundee (44). Antibodies were obtained from the following sources: anti-PPAR{gamma} (Santa Cruz Biotechnology, Santa Cruz, CA), anti-PDK1, anti-Gal-4 and anti-Myc-Tag (Upstate Biotechnology, Lake Placid, NY), horseradish peroxidase-conjugated secondary antibodies (Pierce Chemical, Rockford, IL). GW7845 was kindly provided by GlaxoSmithKline (Research Triangle Park, NC), and rosiglitazone was obtained through the Chemoprevention Branch, National Cancer Institute (Bethesda, MD). Insulin was purchased from Sigma-Aldrich Chemical Co.

Plasmids and Plasmid Construction
Plasmid pcDNA3.1-PPAR{gamma}1 was constructed by PCR amplification of full-length human PPAR{gamma}1 from pPax8-PPAR{gamma}1 (45) (kindly provided by Dr. Todd G. Kroll, University of Chicago, Chicago, IL) and subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA). Gal4-PPAR{gamma}1 and Gal4-LBD were constructed by PCR amplification from human PPAR{gamma}1 and cloned into pBind (Promega, Madison, WI) in-frame with the Gal4 DNA-binding sequence. pCMV5-MycPDK1 containing hPDK1 or KD-PDK1 with an N-terminal myc-tag (1) was kindly provided by Dr. Dario Alessi. All constructs were confirmed by sequencing and Western blotting of protein extracts from transfected 293T cells. pCDNA3.1-PPAR{gamma}/S225A, pCMV5-mycPDK1/I271R-I272R and pCMV5-mycPDK1/L316R-L317W were prepared by site directed mutagenesis with QuikChange (Stratagene, La Jolla, CA), and the appropriate pair of primers expressing the mutation, and confirmed by sequencing. The PDK1 fragment containing {alpha}-helices F-H and an N-terminal myc-tag (pCMV5-mycPDK1 [256–322]) was prepared by PCR amplification and the sequence confirmed by sequencing. Reporter plasmid, p3XPPRE-thymidine kinase (TK)-Luciferase (14) was generously provided by Dr. Mitchell Lazar (University of Pennsylvania, Philadelphia, PA). pcDNA3-AIB1 was kindly provided by Dr. Anna Riegel (Georgetown University, Washington, DC).

Reporter Assays
293T cells were grown in 24-well plates in DMEM containing 10% fetal calf serum; after 24 h, medium was replaced with DMEM containing 10% delipidated fetal calf serum (Sigma-Aldrich Chemical Co.). Cells were transfected using calcium phosphate precipitation (Promega) with the appropriate combination of luciferase reporter plasmid (p3XPPRE-TK-Luc for PPAR{gamma} or pG5Luc for Gal4 fusion proteins), vector expressing the gene of interest and empty control vector. After 24 h, cells were treated with 1.0 µM GW7845, and luciferase activity was measured 24 h after GW7845 treatment with the luciferase assay system (Promega).

Immunoprecipitation and Western Blotting
293T cells were cotransfected with PPAR{gamma}1 and PDK1 expression plasmids, and protein lysates prepared after 24 h by extraction in modified RIPA buffer [50 mM Tris (pH 7.4), 0.5% Nonidet P-40, 0.25% Na-deoxycholate, 125 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na3VO4 and protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN)] on ice for 1 h. Cells were sonicated for 10 sec, lysates centrifuged at 12,000 x g for 15 min at 4 C, and the supernatant removed for IP. Samples containing 500 µg protein were precleared for 30 min with 30 µl of Protein G Plus/Protein A agarose (Santa Cruz Biotechnology) and incubated for 1 h at 4 C with the appropriate antibodies or normal IgG preadsorbed to Protein G Plus/Protein A agarose. Immune complexes were collected after incubation overnight at 4 C, washed once with lysis buffer and three times with PBS. Protein was eluted by boiling in 50 µl 2x SDS sample buffer [125 mM Tris (pH 6.8), 10% 2-mercaptoethanol, 4% SDS, 20% glycerol], and eluted proteins were analyzed by SDS-PAGE and Western blotting using the appropriate antibodies.

GST-PPAR{gamma} Fusion Proteins
GST-PPAR{gamma} fusion proteins were expressed in BL21 Escherichia coli (Stratagene) and purified using glutathione-Sepharose 4B (Pharmacia Biotech). Beads were washed four times with PBS, and GST fusion proteins eluted with 10 mM reduced glutathione (Sigma-Aldrich Chemical). Protein purity was determined by SDS-PAGE in 4–20% Tris-glycine gels (Invitrogen) and stained with SimplyBlue Safestain (Invitrogen).

In Vitro Phosphorylation
PDK1 (25 ng) (Upstate Biotechnology) was incubated for 30 min with either GST-PPAR{gamma} (250 ng) or 25 ng SGK as substrate, and 10 µCi [{gamma}32P]ATP (Amersham-Pharmacia, Pittsburgh, PA), 100 µM ATP, 10 mM magnesium acetate, 50 mM Tris-HCl (pH 7.5), 0.1 mM EGTA, 0.1 mM EDTA, and 1 µM microcystin at 30 C. Reactions were stopped by addition of SDS sample buffer, boiled for 5 min and loaded onto a 10% Tris-glycine gel (Invitrogen). Proteins were transfer to 0.2 µm nitrocellulose and analyzed by autoradiography.

Viral Transduction of COMMA-1D Cells
Retroviral vector pCMV/hyg was generated by replacement of the Tet on/off control element on vector pRevTRE (CLONTECH, Inc., Palo Alto, CA) with the CMV promoter from pRc/CMV (Invitrogen) (46). Either pSR{alpha}MSVtkneo or pSR{alpha}SVtkneo encoding PDK1, KD-PDK1, Pax8-PPAR{gamma}, or PPAR{gamma} were cotransfected with the pSV-{psi}–-E-MLV ecotropic vector into 293T cells. After 48 h, the supernatants were collected, mixed with an equal volume of fresh DMEM/F12 medium plus 2X supplement in the presence of 4 µg/ml polybrene, and added to COMMA-1D cells. After four rounds of infection, G418-resistant or hygromycin-resistant COMMA-1D cells were selected for 2 wk. To generate cells coexpressing PPAR{gamma}+PDK1 or PPAR{gamma}+KD-PDK1, a second round of transduction was carried out using amphotropic viruses produced in 293T cells cotransfected with pCMV/hyg-PDK1 or pCMV/hyg-KD-PDK1 and the pSV-{psi}–-A-MLV amphotropic vector. After 2 wk of selection in 50 µg/ml hygromycin, the expression of both genes was confirmed by Western blotting.

ChIP Assay
ChIP analysis was performed following a protocol provided by Upstate Biotechnology under modified conditions. COMMA-1D cells (2 x 107 cells) transduced with either empty virus or a retrovirus expressing PPAR{gamma} and PDK1 were grown in DMEM with 10% FCS. At 70–80% confluence, cells were cross-linked by adding 1.1% formaldehyde buffer containing 100 mM sodium chloride, 1 mM EDTA-Na (pH 8.0), 0.5 mM EGTA-Na, Tris-HCl (pH 8.0) directly to the culture medium for 10 min at 37 C. The medium was aspirated, the cells washed three times with ice-cold PBS containing 10 mM dithiothreitol and protease inhibitors, and lysed with warm 1% SDS buffer and incubated for 10 min on ice. The cell lysates were sonicated to shear DNA to 200-1000 bp, and samples were diluted 10-fold in ChIP dilution buffer (Upstate Biotechnology). To reduce nonspecific background, the cell pellet suspension was precleared with 60 µl of salmon sperm DNA/Protein-A agarose as a 50% slurry (Upstate Biotechnology) for 2 h at 4 C with mixing. Chromatin solutions were precipitated overnight at 4 C using 4 µg of anti-PPAR{gamma} (Santa Cruz sc-7196) and anti-PDK1 (Upstate Biotechnology) with rotation. Rabbit IgG was used as a negative control. Then 60 µl of salmon sperm DNA/Protein-A agarose slurry was added and incubated for 2 h at 4 C with rotation. The antibody/histone complex was collected by centrifugation and washed extensively using the manufacturer’s protocol. Input and immunoprecipitated chromatin were incubated at 65 C overnight to reverse cross-linking. After proteinase K digestion for 1 h, DNA was extracted using QIAGEN (Valencia, CA) spin columns, and precipitated DNA was analyzed by PCR of 30 cycles. The following primers were used for PCR to identify PPAR{gamma}-responsive elements: mouse LPL promoter, 5'-AAACCCCTCCTCTCTGCCTC-3' and 5'-CCTCGGAGGAGGAGTAGGAG-3'; mouse aP2 promoter, 5'-CAAGCCATGCGACAAAGGCA-3' and 5'-TAGAAGTCGCTCAGGCCACA-3' (22, 23).

Adipocyte Differentiation
3T3-L1 cells were grown in DMEM supplemented with 10% fetal calf serum in 24-well plates coated with 0.2% gelatin (Sigma-Aldrich Chemical). Cells were transfected with either PDK1 or PPAR{gamma}1 expression plasmids using LipofectaminePlus (Invitrogen). When cells reached confluence after transfection, cells were treated with 5 µg/ml insulin, and 24 h later treated with 0.5 µM rosiglitazone. Medium containing rosiglitazone was replaced every other day for 7 d. Under these conditions (lack of IBMX and dexamethasone), adipocyte differentiation was virtually absent unless cells were transfected with either PPAR{gamma} or PDK1.

COMMA-1D cells were transduced with either empty virus, PPAR{gamma}, PDK1, KD-PDK1, PPAR{gamma}+PDK1 or PPAR{gamma}+KD-PDK1, and grown in 24-well plates in DMEM/F12 medium supplemented with 5% FCS. After reaching confluency, cells were treated as described for 3T3-L1 cells except that 1 µM GW7845 was used in place of rosiglitazone. After 7 d treatment, medium was removed, cells washed twice with PBS and fixed with 10% neutral buffered formalin in PBS for 15 min. Cells were then stained with 0.2% Oil Red O for 15 min or until fat droplets stained intense red, and photographed.

Wild-type mouse ES cells or ES cells containing a homozygous deletion of PDK1 were grown in 12-well plates containing DMEM supplemented with 15% FCS, 0.1 mM nonessential amino acids (Invitrogen), 103 U/ml leukemia inhibitory factor, and ß-mercaptoethanol, 7 µl/liter. After 24 h, cells were treated with 10 nM retinoic acid for 9 d (47), followed by treatment with 1 µM rosiglitazone for 10 d. Medium was then removed, cells washed twice with PBS, and fixed with 10% neutral buffered formalin in PBS for 15 min. Cells were then stained with 0.2% oil red O for 15 min or until fat droplets stained intense red, and cells photographed.

Adipocyte differentiation was also quantitated by use of the AdipoRed Assay Reagent (Cambrex, East Rutherford, NJ). After treatment of COMMA-1D cells with GW7845 as described above, cells were stained with AdipoRed reagent according to the manufacturer’s instructions. Fluorescence was measured in an Ultra384 fluorimeter (Tecan, Durham, NC) with excitation at 485 nm and emission at 535 nm. Three independent experiments were performed and the mean RFU value and SD were calculated.

Molecular Modeling
In the reported crystal structure of the catalytic domain of PDK1 (PDB ID: 1H1W) (20), two sequences were identified within the catalytic domain of PDK1 with potential LXXLL coactivator motifs, 268LGCII272 and 313VEKLL317. The first motif lies within {alpha}-helix F, whereas the second motif resides near the C terminus of {alpha}-helix H. However, comparison of the reported crystal structure of the coactivator LXLL motif/PPAR{gamma} complex (48) with that of 268LGCII272 within {alpha}-helix H revealed interference through van der Waals interactions due to positional effects of 268LGCII272 within the middle of a long {alpha}-helix. However, an alternate LXLL motif denoted by 271IIYQL275 occurred within {alpha}-helix F reading from the C terminus, and because these residues lie within a helix, the direction of the LXXLL moiety for interaction with PPAR becomes irrelevant. By superimposing the appropriate residues of IIYQL with that of the coactivator sequence, a model of the complex between PPAR{gamma} and the PDK1 domain encompassing {alpha}-helix F through H was generated (see Fig. 8Go). The coordinates for the whole complex were then subjected to energy minimization using AMBER force-field (49).


   FOOTNOTES
 
This work was supported by grants from the National Institutes of Health (NIH) (R01CA81565 and N01CN15017-44) to R.I.G. (R01CA70896, R01CA75503, R01CA86072, and R01CA86071) (to R.G.P.), and by a Comprehensive Cancer Center Support Grant from the NIH to the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center.

First Published Online September 8, 2005

Abbreviations: AIB1, Activated in breast cancer-1; AKT, protein kinase B; aP2, adipocyte fatty acid-binding protein; ChIP, chromatin immunoprecipitation; FCS, fetal calf serum; IP, immunoprecipitation; KD, kinase-dead; LBD, ligand binding domain; LPL, lipoprotein lipase; PDK1, 3-phosphoinositide-dependent protein kinase-1; PI3-K, phosphatidylinositol 3-kinase; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; SGK, serum- and glucocorticoid-activated protein kinase; SMRT, silencing mediator of retinoid and thyroid hormone receptors; TK, thymidine kinase.

Received for publication May 18, 2005. Accepted for publication September 1, 2005.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Alessi DR, Deak M, Cassamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M 1997 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7:776–789[CrossRef][Medline]
  2. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT 1998 Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279:710–714[Abstract/Free Full Text]
  3. Blume-Jensen P, Hunter T 2001 Oncogenic kinase signalling. Nature 411:355–365[CrossRef][Medline]
  4. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P 1997 Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B{alpha}. Curr Biol 7:261–269[CrossRef][Medline]
  5. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA 1996 Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541–6551[Medline]
  6. Storz P, Toker A 2002 3'-Phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 7:d886–d902
  7. Magun R, Burgering BM, Coffer PJ, Pardasani D, Lin Y, Chabot J, Sorisky A 1996 Expression of a constitutively activated form of protein kinase B (c-Akt) in 3T3-L1 preadipose cells causes spontaneous differentiation. Endocrinology 137:3590–3593[Abstract]
  8. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O’Rahilly S, Barroso I 2004 A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304:1325–1328[Abstract/Free Full Text]
  9. Willson TM, Brown PJ, Sternbach DD, Henke BR 2000 The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550[CrossRef][Medline]
  10. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}). J Biol Chem 270:12953–12956[Abstract/Free Full Text]
  11. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416–2422[Medline]
  12. Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR{gamma}2, a lipid-activated transcription factor. Cell 79:1147–1156[CrossRef][Medline]
  13. Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM 2002 Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor {gamma} isoforms. J Biol Chem 277:41925–41930[Abstract/Free Full Text]
  14. Li Y, Lazar MA 2002 Differential gene regulation by PPAR{gamma} agonist and constitutively active PPAR{gamma}2. Mol Endocrinol 16:1040–1048[Abstract/Free Full Text]
  15. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB 2002 Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-{gamma} agonists. Endocrinology 143:2106–2118[Abstract/Free Full Text]
  16. Tamori Y, Masugi J, Nishino N, Kasuga M 2002 Role of peroxisome proliferator-activated receptor-{gamma} in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51:2045–2055[Abstract/Free Full Text]
  17. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS 1997 Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}). Differential activity of PPAR{gamma}1 and -2 isoforms and influence of insulin. J Biol Chem 272:20230–20235[Abstract/Free Full Text]
  18. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968[Abstract/Free Full Text]
  19. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S 2000 Ligand type-specific interactions of peroxisome proliferator-activated receptor {gamma} with transcriptional coactivators. J Biol Chem 275:33201–33204[Abstract/Free Full Text]
  20. Biondi RM, Komander D, Thomas CC, Lizcano JM, Deak M, Alessi DR, van Aalten DM 2002 High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J 21:4219–4228[CrossRef][Medline]
  21. Iannone MA, Consler TG, Pearce KH, Stimmel JB, Parks DJ, Gray JG 2001 Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. Cytometry 44:326–337[CrossRef][Medline]
  22. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, Li Z, Yao TP, Pestell RG 2005 Cyclin D1 inhibits peroxisome proliferator-activated receptor {gamma}-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 280:16934–16941[Abstract/Free Full Text]
  23. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG 2004 Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 24:7598–7611[Abstract/Free Full Text]
  24. Vernochet C, Milstone DS, Iehle C, Belmonte N, Phillips B, Wdziekonski B, Villageois P, Amri EZ, O’Donnell PE, Mortensen RM, Ailhaud G, Dani C 2002 PPAR{gamma}-dependent and PPAR{gamma}-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett 510:94–98[CrossRef][Medline]
  25. Kopelovich L, Ray JR, Glazer RI, Crowell JA 2002 Peroxisome proliferator-activated receptor modulators as chemopreventive agents. Mol Cancer Ther 1:357–363[Abstract/Free Full Text]
  26. Berger J, Moller DE 2002 The mechanisms of action of PPARs. Annu Rev Med 53:409–435[CrossRef][Medline]
  27. Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K, Fleckner J 2002 Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes 51:1042–1051[Abstract/Free Full Text]
  28. Shao D, Lazar MA 1997 Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein {alpha}, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272:21473–21478[Abstract/Free Full Text]
  29. Gelman L, Fruchart JC, Auwerx J 1999 An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 55:932–943[CrossRef][Medline]
  30. Grimaldi PA 2001 The roles of PPARs in adipocyte differentiation. Prog Lipid Res 40:269–281[CrossRef][Medline]
  31. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK 1997 Transcriptional activation by peroxisome proliferator-activated receptor {gamma} is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128–5132[Abstract/Free Full Text]
  32. Cohen P, Alessi DR, Cross DA 1997 PDK1, one of the missing links in insulin signal transduction? FEBS Lett 410:3–10[CrossRef][Medline]
  33. Scheid MP, Woodgett JR 2001 PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2:760–768[CrossRef][Medline]
  34. Lim MA, Kikani CK, Wick MJ, Dong LQ 2003 Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function. Proc Natl Acad Sci USA 100:14006–14011[Abstract/Free Full Text]
  35. Komander D, Kular G, Deak M, Alessi DR, van Aalten DM 2005 Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding. J Biol Chem 280:18797–18802[Abstract/Free Full Text]
  36. Tian X, Rusanescu G, Hou W, Schaffhausen B, Feig LA 2002 PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism. EMBO J 21:1327–1338[CrossRef][Medline]
  37. Akaike M, Che W, Marmarosh NL, Ohta S, Osawa M, Ding B, Berk BC, Yan C, Abe J 2004 The hinge-helix 1 region of peroxisome proliferator-activated receptor {gamma}1 (PPAR{gamma}1) mediates interaction with extracellular signal-regulated kinase 5 and PPAR{gamma}1 transcriptional activation: involvement in flow-induced PPAR{gamma} activation in endothelial cells. Mol Cell Biol 24:8691–8704[Abstract/Free Full Text]
  38. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-{gamma}. Nature 395:137–143[CrossRef][Medline]
  39. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG, Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920–2925[Abstract/Free Full Text]
  40. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPAR{gamma}2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234[Abstract/Free Full Text]
  41. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPAR{gamma} is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611–617[CrossRef][Medline]
  42. Morroni M, Giordano A, Zingaretti MC, Boiani R, De Matteis R, Kahn BB, Nisoli E, Tonello C, Pisoschi C, Luchetti MM, Marelli M, Cinti S 2004 Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci USA 101:16801–16806[Abstract/Free Full Text]
  43. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA 2005 Corepressors selectively control the transcriptional activity of PPAR{gamma} in adipocytes. Genes Dev 19:453–461[Abstract/Free Full Text]
  44. Williams MR, Arthur JS, Balendran A, van der Kaay J, Poli V, Cohen P, Alessi DR 2000 The role of 3-phosphoinositide-dependent protein kinase 1 in activating AGC kinases defined in embryonic stem cells. Curr Biol 10:439–448[CrossRef][Medline]
  45. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPAR{gamma}1 fusion oncogene in human thyroid carcinoma. Science [Erratum (2000) 289:1474]289:1357–1360
  46. Zeng X, Xu H, Park B-K, Glazer RI 2002 Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase C{alpha}. Cancer Res 62:3538–3543[Abstract/Free Full Text]
  47. Dani C 2002 Differentiation of embryonic stem cells as a model to study gene function during the development of adipose cells. Methods Mol Biol 185:107–116[Medline]
  48. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe Jr RT, McKee DD, Moore JT, Willson TM 2001 Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98:13919–13924[Abstract/Free Full Text]
  49. Case DA, Pearlman DA, Caldwell JW, Cheatham Spaceiiiqq TE, Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Gohlke H, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA 2002 AMBER 7, University of California, San Francisco
  50. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE 2000 The Protein Data Bank. Nucleic Acids Res 28:235–242[Abstract/Free Full Text]

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARγ
Coregulators:   AIB1  |  SMRT
Ligands:   all-trans-Retinoic acid  |  Rosiglitazone




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/2/268    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yin, Y.
Right arrow Articles by Glazer, R. I.
Right arrow Search for Related Content
PubMed
Right arrow